Answers are grounded in this paper and cite their sources.
Systematic review reports improved survival and mechanical support use in cardiogenic shock with PAC, indicating clinical implications.
Background The role of pulmonary artery catheterization (PAC) in cardiogenic shock (CS) remains debated, with prior ICU trials showing no benefit, but contemporary registries suggesting improved outcomes. However, the overall evidence remains fragmented, with inconsistent phenotypic and outcome reporting. Purpose To assess, through a meta-analysis of contemporary observational and registry studies, whether PAC use in CS is associated with survival benefit, mechanical circulatory support (MCS) use, and sepsis; and to examine trends by phenotype and practice era. Methods Systematic review and meta-analysis of 14 studies from North America, Europe, and Asia, including 789,553 adult CS patients. Primary endpoint: short-term mortality. Secondary endpoints: MCS use [intra-aortic balloon pump (IABP), Impella, extracorporeal membrane oxygenation (ECMO)], and sepsis. Odds ratios (OR) were pooled using random-effects models and hazard ratios (HR) fixed-effects guides by the heterogenecity; trial sequential analysis (TSA) and meta-regression by publication year were performed. Results Mortality: PAC use reduced short-term mortality (OR 0.70, 95% CI 0.63–0.78; I² = 97%). In seven studies (5,142 pts), PAC lowered hazard of death by 32% (HR 0.68, 95% CI 0.60–0.77; I² = 34%). Subgroup benefit was consistent in AMI-CS (OR 0.77), HF-CS (OR 0.58), and mixed CS (OR 0.72). MCS: PAC was associated with higher MCS use (OR 2.76, 95% CI 1.82–4.20). After trim-and-fill, adjusted OR was 3.98. Absolute rates: IABP 36.5% vs 23.4%; Impella 15–22% vs 2–3%; ECMO 4–6% vs 1–2%. Sepsis: PAC increased infection risk (OR 1.83, 95% CI 1.42–2.35; I² = 61%), with absolute rates 5–9% vs 3–7% in controls. Other outcomes: PAC groups more often were offered more vasoactive/inotropes (10–17% vs 8–12%), had higher RRT use (up to 10.7% vs 8.1%), and longer ICU stay (~2–3 days). Heterogeneity: TSA confirmed conclusive survival benefit. Meta-regression showed stronger survival and MCS associations in recent years (R² = 0.57, p = 0.002), reflecting integration into structured shock protocols. Other results: Study quality and bias: Most studies scored ≥7/9 on Newcastle–Ottawa scale; no publication bias detected for mortality or sepsis (Egger p>0.10); trim-and-fill analyses confirmed robustness. Conclusions In 14 observational studies and nearly 800,000 CS patients, PAC monitoring was consistently associated with improved survival and greater MCS use, but also increased sepsis and resource utilization. These findings support protocol-driven PAC deployment within shock teams, tailored to phenotype, and underscore the urgent need for randomized trials to define optimal timing and balance of benefit versus risk.Central figure
No takes yet. Share an insight, caveat, or question.
Ortega-Hernandez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: